Up-regulation of hepatic low-density lipoprotein receptor–related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl–coenzyme A reductase inhibitor
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Low-density lipoprotein receptor-related protein 1 (LRP1) binds to apolipoprotein E and serves as a receptor for remnant lipoproteins in the liver, thus playing an important role in clearing these atherogenic particles. In this study, we investigated the effect of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, on hepatic LRP1 expression. We used HepG2 and Hep3B cells for in vitro study, and Otsuka Long-Evans Tokushima fatty and Sprague-Dawley rats for in vivo study. We used relatively high pharmacologic dose of atorvastatin in this study (in vitro, 0.5 μmol/L in culture media, for 48 hours; in vivo, 20 mg/[kg d], for 6 weeks). Atorvastatin increased LRP1 and low-density lipoprotein (LDL) receptor expression in HepG2 and Hep3B cells and induced hepatic LRP1 and LDL receptor expression in chow diet-fed Sprague-Dawley rats and high-fat diet-fed Otsuka Long-Evans Tokushima fatty rats. Atorvastatin decreased intracellular sterol level and increased the amount of the nuclear form of sterol response element-binding protein-2 (SREBP-2) in both HepG2 and Hep3B cells as well as in two animal models. Treatment of HepG2 cells with LDL increased intracellular sterol level and reduced LRP1, LDL receptor, and SREBP-2. When SREBP-2 in HepG2 cells was knocked down by small interfering RNA, the induction of LRP1 expression by atorvastatin did not take place. In conclusion, up-regulation of hepatic LRP1 might be a novel mechanism by which statin treatment decreases remnant lipoproteins. In addition, SREBP-2 acts as a mediator of atorvastatin-induced up-regulation of hepatic LRP1. Future studies using standard doses of atorvastatin in humans are needed to elucidate clinical relevance of these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
Hepatic uptake of chylomicron remnants
Cooper, A. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34932-4 · Cited by 499
Rohlmann, A., Gotthardt, M., Hammer, R. E., & Herz, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1240 · Cited by 455 · cited 1×
“Furthermore, LRP1 plays an important role in the clearance of remnant of triglyceride-rich lipoproteins such as chylomicron remnant or very lowdensity lipoprotein remnant [3,4].”
Background
Cited by
Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Causes and consequences of hypertriglyceridemia
Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239
Is Alzheimer’s Disease a Liver Disease of the Brain?
Bassendine, M. F., Taylor-Robinson, S. D., Fertleman, M., Khan, M., & Neely, D. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-190848 · Cited by 124
“protein-2 (SREBP-2) in vitro and in vivo [38].”
BackgroundSynthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid
Vu, C. B., Bemis, J. E., Benson, E., Bista, P., Carney, D., Fahrner, R., Lee, D., Liu, F., Lonkar, P., Milne, J. C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01961 · Cited by 27
Metadata
- Authors
- Moon, J. H., Kang, S. B., Park, J. S., Lee, B. W., Kang, E. S., Ahn, C. W., Lee, H. C., & Cha, B. S.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 60
- Issue
- 7
- Pages
- 930-940
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W1978664579
- Cited by
- 50
- References
- 3
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Up-regulation of hepatic low-density lipoprotein receptor–related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl–coenzyme A reductase inhibitor. https://app.cochat.ai/papers/10.1016/j.metabol.2010.08.013
- The paper
- Moon, J. H., Kang, S. B., Park, J. S., Lee, B. W., Kang, E. S., Ahn, C. W., Lee, H. C., & Cha, B. S. (2011). Up-regulation of hepatic low-density lipoprotein receptor–related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl–coenzyme A reductase inhibitor. Metabolism. https://doi.org/10.1016/j.metabol.2010.08.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.